Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer
Acta Pharmacologica Sinica · 2024-06 · 45 (6) · 1264-1275
DOI: 10.1038/s41401-024-01237-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmacologica Sinica, online erschienen am 04.03.2024. Verfasst von Rui Han und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, 400042, China. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Antineoplastic Agents, Axl Receptor Tyrosine Kinase. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
In addition to the classical resistance mechanisms, receptor tyrosine-protein kinase AXL is a main mechanism of resistance to third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) osimertinib in EGFR-mutated non-small cell lung cancer (NSCLC). Developing an effective AXL inhibitor is important to sensitize osimertinib in clinical application. In this study we assessed the efficacy of brigatinib, a second-generation of anaplastic lymphoma kinase (ALK)-TKI, as a novel AXL inhibitor, in overcoming acquired resistance to osimertinib induced by AXL activation. We established an AXL-overexpression NSCLC cell line and conducted high-throughput screening of a small molecule chemical library containing 510 anti-tumor drugs. We found that brigatinib potently inhibited AXL expression, and that brigatinib (0.5 μM) significantly enhanced the anti-tumor efficacy of osimertinib (1 μM) in AXL-mediated osimertinib-resistant NSCLC cell lines in vitro. We demonstrated that brigatinib had a potential ability to bind AXL kinase protein and further inhibit its downstream pathways in NSCLC cell lines. Furthermore, we revealed that brigatinib might decrease AXL expression through increasing K48-linked ubiquitination of AXL and promoting AXL degradation in HCC827OR cells and PC-9OR cells. In AXL-high expression osimertinib-resistant PC-9OR and HCC827OR cells derived xenograft mouse models, administration of osimertinib (10 mg·kg-1·d-1) alone for 3 weeks had no effect, and administration of brigatinib (25 mg·kg-1·d-1) alone caused a minor inhibition on the tumor growth; whereas combination of osimertinib and brigatinib caused marked tumor shrinkages. We concluded that brigatinib may be a promising clinical strategy for enhancing osimertinib efficacy in AXL-mediated osimertinib-resistant NSCLC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, 400042, China.
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400044, China.
- Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, 400042, China. heyong@tmmu.edu.cn.
Zitieren
APA
Han, R., Lu, C. H., Hu, C., Dou, Y. Y., Kang, J., Lin, C. Y., Wu, D., Jiang, W. L., Yin, G. Q., & He, Y. (2024). Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer. Acta Pharmacologica Sinica, 45(6), 1264-1275. https://doi.org/10.1038/s41401-024-01237-4
Vancouver
Han R, Lu CH, Hu C, Dou YY, Kang J, Lin CY, et al. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer. Acta Pharmacologica Sinica. 2024;45(6):1264-1275. doi:10.1038/s41401-024-01237-4
BibTeX
@article{Han2024,
author = {Han, Rui and Lu, Cong-Hua and Hu, Chen and Dou, Yuan-Yao and Kang, Jun and Lin, Cai-Yu and Wu, Di and Jiang, Wei-Ling and Yin, Guo-Qing and He, Yong},
title = {Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer},
journal = {Acta Pharmacologica Sinica},
year = {2024},
volume = {45},
number = {6},
pages = {1264--1275},
doi = {10.1038/s41401-024-01237-4}
}
EUVIMED